Tumor-derived cfDNA is present in body fluids of cancer patients. Hence, liquid profiling is a promising minimal-invasive tool with great diagnostic and monitoring potential. It can complement invasive biopsies that provide only a snapshot of an often heterogeneous tumor. In contrast, repeated liquid profiling can track changes over time and detect tumor resistance occurring during therapy.
Here, we discuss the emerging role of cfDNA in cancer and the current landscape of applications in oncology.